Asset Details
Do you wish to reserve the book?
Debugging Nano–Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Debugging Nano–Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies
Do you wish to request the book?
Debugging Nano–Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Debugging Nano–Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies
2018
Overview
Despite considerable efforts in the field of nanomedicine that have been made by researchers, funding agencies, entrepreneurs, and the media, fewer nanoparticle (NP) technologies than expected have made it to clinical trials. The wide gap between the efforts and effective clinical translation is, at least in part, due to multiple overlooked factors in both in vitro and in vivo environments, a poor understanding of the nano–bio interface, and misinterpretation of the data collected in vitro, all of which reduce the accuracy of predictions regarding the NPs’ fate and safety in humans. To minimize this bench-to-clinic gap, which may accelerate successful clinical translation of NPs, this opinion paper aims to introduce strategies for systematic debugging of nano–bio interfaces in the current literature.
Critical information on nano–bio interfaces (e.g., biomolecular corona) and cells, including their sex, type, size, and passage number, should be considered.
Standardization communities should propose standard units for nanoparticle dosage.
Mathematical and computational approaches should be developed to define underlying mechanisms at the nano–bio interfaces.
Interlaboratory comparison of characterization of nanoparticles, nano–bio interfaces, nanotoxicities, therapeutic efficacies, and others should be conducted to prevent conflicts produced by different instruments.
Researchers, various well-established laboratories, funding agencies, entrepreneurs, and the media should work closely to prepare reliable and precise data sets, not only to prevent further clutter in the nanomedicine literature but also to accelerate successful clinical translation of nanomedicine.
